Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA. Kawamori R, et al. Among authors: hayashi n. Diabetes Obes Metab. 2012 Apr;14(4):348-57. doi: 10.1111/j.1463-1326.2011.01545.x. Epub 2012 Jan 17. Diabetes Obes Metab. 2012. PMID: 22145698 Clinical Trial.
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: hayashi n. Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004. Clin Ther. 2010. PMID: 20637971 Clinical Trial.
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA. Horie Y, et al. Among authors: hayashi n. Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2. Clin Ther. 2011. PMID: 21723606 Clinical Trial.
Renoprotective effects of telmisartan on renal injury in obese Zucker rats.
Ohmura T, Tsunenari I, Seidler R, Chachin M, Hayashi T, Konomi A, Matsumaru T, Sumida T, Hayashi N, Horie Y. Ohmura T, et al. Among authors: hayashi t, hayashi n. Acta Diabetol. 2012 Dec;49 Suppl 1:S15-24. doi: 10.1007/s00592-007-0016-5. Epub 2007 Nov 16. Acta Diabetol. 2012. PMID: 18008027
Renoprotective effects of telmisartan in the 5/6 nephrectomised rats.
Tsunenari I, Ohmura T, Seidler R, Chachin M, Hayashi T, Konomi A, Matsumaru T, Sumida T, Hayashi N, Horie Y. Tsunenari I, et al. Among authors: hayashi t, hayashi n. J Renin Angiotensin Aldosterone Syst. 2007 Jun;8(2):93-100. doi: 10.3317/jraas.2007.017. J Renin Angiotensin Aldosterone Syst. 2007. PMID: 17703436 Free article.
3,562 results